Scribd Logo
Upload

Welcome to Scribd!

    • 35 views

    A Review of The Costs of Managing

    Uploaded by

    Apsopela Sandivera
    A review of studies on the economic costs of managing childhood epilepsy found that the mean annual cost per child with controlled epilepsy was $1853 USD in Spain in 1998, while the cost for uncontrolled epilepsy was $4950 USD. An Italian study from 1996-1998 found annual direct costs ranged from €844 for children in remission to €3268 for those with drug-resistant epilepsy. Most costs were from hospital admissions and medications, with costs higher for more severe epilepsy and frequent seizures. Early treatment is important to reduce indirect costs when the child becomes an adult.

    Copyright:

    Attribution Non-Commercial (BY-NC)
    Download as DOCX, PDF, TXT or read online from Scribd

    A Review of The Costs of Managing

    Uploaded by

    Apsopela Sandivera
    35 views2 pages
    A review of studies on the economic costs of managing childhood epilepsy found that the mean annual cost per child with controlled epilepsy was $1853 USD in Spain in 1998, while the cost for uncontrolled epilepsy was $4950 USD. An Italian study from 1996-1998 found annual direct costs ranged from €844 for children in remission to €3268 for those with drug-resistant epilepsy. Most costs were from hospital admissions and medications, with costs higher for more severe epilepsy and frequent seizures. Early treatment is important to reduce indirect costs when the child becomes an adult.

    Original Description:

    doc

    Original Title

    A review of the costs of managing.docx

    Copyright

    © Attribution Non-Commercial (BY-NC)

    Available Formats

    DOCX, PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    A review of studies on the economic costs of managing childhood epilepsy found that the mean annual cost per child with controlled epilepsy was $1853 USD in Spain in 1998, while the cost for uncontrolled epilepsy was $4950 USD. An Italian study from 1996-1998 found annual direct costs ranged from €844 for children in remission to €3268 for those with drug-resistant epilepsy. Most costs were from hospital admissions and medications, with costs higher for more severe epilepsy and frequent seizures. Early treatment is important to reduce indirect costs when the child becomes an adult.

    Copyright:

    Attribution Non-Commercial (BY-NC)
    Download as DOCX, PDF, TXT or read online from Scribd
    Download as docx, pdf, or txt
    35 views2 pages

    A Review of The Costs of Managing

    Uploaded by

    Apsopela Sandivera
    A review of studies on the economic costs of managing childhood epilepsy found that the mean annual cost per child with controlled epilepsy was $1853 USD in Spain in 1998, while the cost for uncontrolled epilepsy was $4950 USD. An Italian study from 1996-1998 found annual direct costs ranged from €844 for children in remission to €3268 for those with drug-resistant epilepsy. Most costs were from hospital admissions and medications, with costs higher for more severe epilepsy and frequent seizures. Early treatment is important to reduce indirect costs when the child becomes an adult.

    Copyright:

    Attribution Non-Commercial (BY-NC)
    Download as DOCX, PDF, TXT or read online from Scribd
    Download as docx, pdf, or txt
    of 2

    A review of the costs of managing childhood epilepsy.

    Beghi E, Frigeni B, Beghi M, De Compadri P, Garattini L.

    Source
    Epilepsy Center, University of Milano-Bicocca, Monza, Italy. [email protected]

    Abstract
    Epilepsy is a chronic treatable condition for which new diagnostic tools and several new drugs and non-pharmacological treatments are now available. The cost profile of these options is assessed here through an overview of the available literature focusing on studies of childhood epilepsy. Several methodological problems arise when interpreting the results of economic studies in epilepsy, including the variability of the study population and costs items, the reliability of the sources of cost, the limitations of the methods of data collection and the deficiencies of the study designs, with reference to the measures of treatment benefits. International comparisons are then difficult because economic results cannot be compared on account of differences in monetary issues, clinical practice patterns and healthcare system frameworks. The economic aspects of epilepsy are different in children and adults. Differences are detectable in the incidence and expression of epileptic syndromes, social and emotional impact, availability of antiepileptic drugs, hospital admissions, diagnostic tests and referral to specialists, social assistants and other healthcare professionals. In addition, children have access to medical services only with the help of a caregiver, for whom there may be lost work days or under-employment. The mean annual cost per child with epilepsy was USD 1853 for controlled epilepsy and USD 4950 for uncontrolled epilepsy in a Spanish study performed in 1998 and the annual direct costs per child with epilepsy ranged from euro 844 for patients in remission to euro 3268 for patients with drug-resistantepilepsy in an Italian study done between 1996 and 1998. The Spanish study showed that direct costs are the major source of expenditure for children with epilepsy. These studies along with a number of other cost-of-illness studies in combined populations of adults and children showed that service use and costs increase with more severe forms of illness and seizure frequency, this being more marked in adults than in children. Moderate cost differences may be expected between children (higher) and adults (lower), particularly with reference to initial investigations. Costs of epilepsyare mostly explained by hospital admissions and drugs; in particular, drug costs tend to dominate in more well controlled epilepsy, while both hospital admissions and drugs are significant costs in less well controlled epilepsy. Newly diagnosed patients can incur significant hospital and diagnostic costs. Costs for epilepsy tend to be lower for patients cared for in general practice or outpatient settings than in hospital settings. Seizure control by drugs, ketogenic diet or surgery is associated with a significant reduction in the costs of epilepsy.

    A review of the costs of managing childhood epilepsy.


    Ettore Beghi, Barbara Frigeni, Massimiliano Beghi, Paola De Compadri, Livio Garattini
    Pharmacoeconomics. 2005; 23(1): 2745.

    Rev Neurol. 2000 Jan 16-31;30(2):104-8.

    [Economic costs of childhood epilepsy in Spain].


    [Article in Spanish]
    Argumosa A, Herranz JL.

    Source
    Servicio de Neuropediatra, Hospital Universitario Marqus de Valdecilla, Santander, Espaa.

    Abstract
    INTRODUCTION: Health expenditure increases continuously in all developed countries. Common disorders, including epilepsy are responsible for most of the health budget. OBJECTIVE: To quantify the economic effect of childhood epilepsy in Spain by analyzing its major components. PATIENTS AND METHODS: We asked a number of neuropediatricians to complete to questionnaire including data from which to calculate, from a social aspect, the direct and indirect costs (medical and non-medical) of the last 12 months follow-up of children under 14 years old with controlled and uncontrolled epilepsy. RESULTS: During 1998, the average annual cost of children with controlled epilepsy was 308,352 pesetas and of children with uncontrolled epilepsy823,635 pesetas, or 2.7 times more. The cost of the prevalence of epilepsy in Spain during 1998 was nearly 11,300 million pesetas with direct costs making up most of the total cost. CONCLUSIONS: The size of the economic aspect increases the impact of the disease on the child and his family. The different cost distribution in children and in adults with epilepsy makes early treatment necessary so as to permit lower indirect costs of the disease when the patient becomes adult. Pharmaco-economic assessment is also necessary to justify the use of newer anti-epileptic drugs which are considerably more expensive than the classical anti-epileptic drugs.
    PMID:

    10730313

    [PubMed - indexed for MEDLINE]

    You might also like